6-[(2-Methoxyethoxy)amino]-5-methylpyrimidin-2(1H)-one | 244105-55-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-[(2-Methoxyethoxy)amino]-5-methylpyrimidin-2(1H)-one
• 英文别名: 6-(2-methoxyethoxyamino)-5-methyl-1H-pyrimidin-2-one
• CAS: 244105-55-3
• 化学式: C₈H₁₃N₃O₃
• 分子量: 199.21
• InChiKey: KNYQCJJWZZCAGS-UHFFFAOYSA-N

物化性质

• 熔点：
  >70°C(dec)
• 沸点：
  536.5±60.0 °C(Predicted)
• 密度：
  1.52
• 溶解度：
  DMSO（少许）、甲醇（少许）、水（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  72
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090

文献信息

• Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
  申请人：——

  公开号：US20030004120A1

  公开（公告）日：2003-01-02

  Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. Methods for inducing apoptosis and for treating diseases or conditions associated with a reduction in apoptosis are also provided.

  提供了用于治疗和诊断适合通过调节编码Jun N末端激酶（JNK蛋白）的基因表达来治疗的疾病或紊乱的组合物和方法。此处提供了专门与编码JNK1、JNK2和JNK3以及其他JNK蛋白和其特定亚型的核酸特异杂交的寡核苷酸。还提供了通过使用这种寡核苷酸调节一个或多个JNK蛋白的表达来治疗患有适合治疗干预的疾病或紊乱的动物的方法。还提供了治疗和诊断与一个或多个JNK蛋白异常表达有关的疾病或紊乱的方法。还提供了诱导细胞凋亡和治疗与凋亡减少有关的疾病或状况的方法。
• COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK PROTEINS
  申请人：Yu Xing-Xian

  公开号：US20080255030A1

  公开（公告）日：2008-10-16

  The invention provides compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase 1 (JNK1 protein.

  该发明提供了一种通过调节编码Jun N末端激酶1（JNK1）蛋白的基因表达来治疗和诊断易于治疗的疾病或障碍的组合物和方法。
• ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK PROTEINS
  申请人：McKay Robert

  公开号：US20070149472A1

  公开（公告）日：2007-06-28

  Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. Methods for inducing apoptosis and for treating diseases or conditions associated with a reduction in apoptosis are also provided.

  提供了用于治疗和诊断可通过调节编码Jun N末端激酶（JNK蛋白）基因表达来治疗的疾病或障碍的组合物和方法。此处提供了寡核苷酸，其与编码JNK1、JNK2和JNK3以及其他JNK蛋白和其特定亚型的核酸特异性杂交。还提供了通过调节一个或多个JNK蛋白的表达来治疗患有可通过治疗干预的疾病或障碍的动物的方法。还提供了用于治疗和诊断与一个或多个JNK蛋白异常表达相关的疾病或障碍的方法。还提供了诱导凋亡和治疗与凋亡减少相关的疾病或病况的方法。
• Oligonucleotides and other modulators of the NK-1 receptor pathway and therapeutic uses thereof
  申请人：——

  公开号：US20030060438A1

  公开（公告）日：2003-03-27

  Methods for administering oligonucleotides, nucleotide analogs, and non-nucleotide disruptor compounds to modulate the NK-1receptor biosynthetic pathway in humans and other mammals are provided. Oligonucleotides, and especially antisense oligonucleotides complementary to nucleic acids in the pathway that produces the NK-1 receptor, and those complementary to nucleic acids in pathways that regulate NK-1 receptor production and function, are useful, inter alia, to reduce pain, inflammation, and the undesirable effects of many diseases and conditions that involve NK-1 receptors. Non-nucleotide disrupter compounds and nucleotide analog compounds that act to modulate the NK-1receptor biosynthetic pathway to thereby regulate NK-1 receptor production and function, are similarly useful. The invention relates also to pharmaceutical preparations for humans and other mammals containing one or more oligonucleotides, nucleotide analogs, or non-nucleotide disrupter compounds.

  提供了给药寡核苷酸、核苷酸类似物和非核苷酸干扰化合物以调节人类和其他哺乳动物体内NK-1受体生物合成途径的方法。寡核苷酸，特别是与产生 NK-1 受体的途径中的核酸互补的反义寡核苷酸，以及与调节 NK-1 受体产生和功能的途径中的核酸互补的反义寡核苷酸，特别有助于减轻疼痛、炎症以及许多涉及 NK-1 受体的疾病和病症的不良影响。非核苷酸干扰物和核苷酸类似物也同样有用，它们能调节 NK-1 受体的生物合成途径，从而调节 NK-1 受体的产生和功能。本发明还涉及含有一种或多种寡核苷酸、核苷酸类似物或非核苷酸干扰化合物的用于人类和其他哺乳动物的药物制剂。
• ANTISENSE MODULATION OF LFA-3
  申请人：ISIS PHARMACEUTICALS, INC.

  公开号：EP1064402B1

  公开（公告）日：2006-02-01